What is Immunome's operating income?

Immunome (IMNM) reported operating income of -$59.33M in Q1 2026.

How has Immunome's operating income changed year-over-year?

Immunome's operating income decreased by 32.9% year-over-year, from -$44.64M to -$59.33M.

What is the long-term trend for Immunome's operating income?

Over 4 years (2021 to 2025), Immunome's operating income has grown at a 72.7% compound annual growth rate (CAGR), from -$25.2M to -$224.11M.

What does operating income mean?

Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.

Immunome IMNM Operating Income

Operating Income at other companies

Arcus BiosciencesRCUS

-$134M-9.8%

SELLAS Life Sciences Group, Inc.SLS

-$9.25M-52.6%

IDEAYA Biosciences, Inc.IDYA

-$108.54M-28.6%

ImmunityBio, Inc.IBRX

-$69.79M-8.3%

ExelixisEXEL

$251.34M+34.5%

Nektar TherapeuticsNKTR

-$39.05M+12.3%

Segments

By segment

See full

Single Reportable-$59.33M-32.9%

Other financials

Income statement

See full

Revenue--100%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's operating income.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's operating income?: Immunome (IMNM) reported operating income of -$59.33M in Q1 2026.
How has Immunome's operating income changed year-over-year?: Immunome's operating income decreased by 32.9% year-over-year, from -$44.64M to -$59.33M.
What is the long-term trend for Immunome's operating income?: Over 4 years (2021 to 2025), Immunome's operating income has grown at a 72.7% compound annual growth rate (CAGR), from -$25.2M to -$224.11M.
What does operating income mean?: Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.